Soleno Therapeutics (SLNO) Stock Forecast & Price Target

Compare

876 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SLNO Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Soleno

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SLNO Stock 12 Month Forecast

Average Price Target

$115.00

▲(150.49% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Soleno Therapeutics in the last 3 months. The average price target is $115.00 with a high forecast of $145.00 and a low forecast of $75.00. The average price target represents a 150.49% change from the last price of $45.91.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"$43","146":"$146","68.75":"$68.8","94.5":"$94.5","120.25":"$120.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$145.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,68.75,94.5,120.25,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.16,73.14769230769231,79.13538461538461,85.12307692307692,91.11076923076922,97.09846153846154,103.08615384615385,109.07384615384615,115.06153846153846,121.04923076923077,127.03692307692307,133.0246153846154,139.0123076923077,{"y":145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.16,70.84,74.52,78.2,81.88,85.56,89.24,92.92,96.6,100.28,103.96000000000001,107.64,111.32,{"y":115,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.16,67.76307692307692,68.36615384615385,68.96923076923076,69.57230769230769,70.17538461538462,70.77846153846154,71.38153846153845,71.98461538461538,72.58769230769231,73.19076923076923,73.79384615384615,74.39692307692307,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":55.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$145.00

Average Price Target$115.00

Lowest Price Target$75.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

$75

Buy

63.36%

Upside

Initiated

11/17/25

Soleno Therapeutics initiated with an Outperform at Wolfe ResearchSoleno Therapeutics initiated with an Outperform at Wolfe Research

Ram Selvaraju

H.C. Wainwright

$110

Buy

139.60%

Upside

Reiterated

11/10/25

Soleno Therapeutics: Strong Q3 Performance and Market Potential Justify Buy RatingValuation and Risks. We have employed a discounted cash flow (DCF)-based approach to assess Soleno's prospects. This utilizes a 10% discount rate, 2% terminal growth rate and 29.84% effective tax rate. We ascribe a 100% probability of U.S. regulatory approval to Soleno's sole marketed product, VYKAT XR (formerly DCCR). Given these parameters, we derive a total firm value of $6.25B, which translates into a 12-month price objective of $110 per share assuming ~56.8M shares outstanding as of mid-2026. Risks include, but are not limited to: (1) slower-than-expected U.S.

Tyler Van Buren

TD Cowen

$115→$120

Buy

161.38%

Upside

Reiterated

11/07/25

Soleno Therapeutics: Strong Sales Growth and Profitability Drive Buy Rating

Derek Archila

Wells Fargo

$123→$106

Buy

130.89%

Upside

Reiterated

11/05/25

Soleno Therapeutics price target lowered to $106 from $123 at Wells FargoSoleno Therapeutics price target lowered to $106 from $123 at Wells Fargo

James Condulis

Stifel Nicolaus

$115

Buy

150.49%

Upside

Reiterated

11/05/25

Stifel Nicolaus Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

Kate Dellorusso

LifeSci Capital

$120→$110

Buy

139.60%

Upside

Reiterated

11/05/25

LifeSci Capital Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)we have updated our price target to $110 per share

Kristen Kluska

Cantor Fitzgerald

$123

Buy

167.92%

Upside

Reiterated

11/04/25

Cantor Fitzgerald Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

Paul Choi

Goldman Sachs

$125

Buy

172.27%

Upside

Initiated

10/07/25

Buy Rating for Soleno Therapeutics: Strong Market Potential and Growth Opportunities with Vykat XR

Yasmeen Rahimi

Piper Sandler

$145

Buy

215.84%

Upside

Reiterated

10/03/25

Piper Sandler Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

Brian Skorney

Robert W. Baird

$121

Buy

163.56%

Upside

Reiterated

09/25/25

Robert W. Baird Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

Leland Gershell

Oppenheimer

$110

Buy

139.60%

Upside

Reiterated

08/25/25

Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (NASDAQ: SLNO) and Hinge Health, Inc. Class A (NYSE: HNGE)We reiterate Outperform and would take advantage of the recent weakness following the short report.

Debjit Chattopadhyay

Guggenheim

$97→$106

Buy

130.89%

Upside

Reiterated

08/06/25

Guggenheim Keeps Their Buy Rating on Soleno Therapeutics (SLNO)

Yale Jen

Laidlaw

$75→$105

Buy

128.71%

Upside

Reiterated

03/27/25

Soleno Therapeutics price target raised to $105 from $75 at LaidlawSoleno Therapeutics price target raised to $105 from $75 at Laidlaw

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

$75

Buy

63.36%

Upside

Initiated

11/17/25

Soleno Therapeutics initiated with an Outperform at Wolfe ResearchSoleno Therapeutics initiated with an Outperform at Wolfe Research

Ram Selvaraju

H.C. Wainwright

$110

Buy

139.60%

Upside

Reiterated

11/10/25

Tyler Van Buren

TD Cowen

$115→$120

Buy

161.38%

Upside

Reiterated

11/07/25

Soleno Therapeutics: Strong Sales Growth and Profitability Drive Buy Rating

Derek Archila

Wells Fargo

$123→$106

Buy

130.89%

Upside

Reiterated

11/05/25

Soleno Therapeutics price target lowered to $106 from $123 at Wells FargoSoleno Therapeutics price target lowered to $106 from $123 at Wells Fargo

James Condulis

Stifel Nicolaus

$115

Buy

150.49%

Upside

Reiterated

11/05/25

Stifel Nicolaus Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

Kate Dellorusso

LifeSci Capital

$120→$110

Buy

139.60%

Upside

Reiterated

11/05/25

LifeSci Capital Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)we have updated our price target to $110 per share

Kristen Kluska

Cantor Fitzgerald

$123

Buy

167.92%

Upside

Reiterated

11/04/25

Cantor Fitzgerald Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

Paul Choi

Goldman Sachs

$125

Buy

172.27%

Upside

Initiated

10/07/25

Buy Rating for Soleno Therapeutics: Strong Market Potential and Growth Opportunities with Vykat XR

Yasmeen Rahimi

Piper Sandler

$145

Buy

215.84%

Upside

Reiterated

10/03/25

Piper Sandler Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

Brian Skorney

Robert W. Baird

$121

Buy

163.56%

Upside

Reiterated

09/25/25

Robert W. Baird Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

Leland Gershell

Oppenheimer

$110

Buy

139.60%

Upside

Reiterated

08/25/25

Debjit Chattopadhyay

Guggenheim

$97→$106

Buy

130.89%

Upside

Reiterated

08/06/25

Guggenheim Keeps Their Buy Rating on Soleno Therapeutics (SLNO)

Yale Jen

Laidlaw

$75→$105

Buy

128.71%

Upside

Reiterated

03/27/25

Soleno Therapeutics price target raised to $105 from $75 at LaidlawSoleno Therapeutics price target raised to $105 from $75 at Laidlaw

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Soleno Therapeutics

1 Month

xxx

Success Rate

6/10 ratings generated profit

Average Return

+1.94%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +1.94% per trade.

3 Months

xxx

Success Rate

7/11 ratings generated profit

Average Return

+77.85%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +77.85% per trade.

1 Year

Kristen KluskaCantor Fitzgerald

Success Rate

6/11 ratings generated profit

Average Return

+156.24%

reiterated a buy rating 23 days ago

Copying Kristen Kluska's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +156.24% per trade.

2 Years

xxx

Success Rate

5/11 ratings generated profit

Average Return

+148.53%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 45.45% of your transactions generating a profit, with an average return of +148.53% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SLNO Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SLNO has received 26 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SLNO average Analyst price target in the past 3 months is 115.00.

Each month's total comprises the sum of three months' worth of ratings.

SLNO Financial Forecast

SLNO Earnings Forecast

Next quarter’s earnings estimate for SLNO is $0.61 with a range of $0.25 to $1.02. The previous quarter’s EPS was $0.47. SLNO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year SLNO has Performed in-line its overall industry.

SLNO Sales Forecast

Next quarter’s sales forecast for SLNO is $83.31M with a range of $72.10M to $100.88M. The previous quarter’s sales results were $66.02M. SLNO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year SLNO has Performed in-line its overall industry.

SLNO Stock Forecast FAQ

What is SLNO’s average 12-month price target, according to analysts?

Based on analyst ratings, Soleno Therapeutics Inc’s 12-month average price target is 115.00.

What is SLNO’s upside potential, based on the analysts’ average price target?

Soleno Therapeutics Inc has 150.49% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SLNO a Buy, Sell or Hold?

Soleno Therapeutics Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Soleno Therapeutics Inc’s price target?

The average price target for Soleno Therapeutics Inc is 115.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $145.00 ,the lowest forecast is $75.00. The average price target represents 150.49% Increase from the current price of $45.91.

What do analysts say about Soleno Therapeutics Inc?

Soleno Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of SLNO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Soleno Therapeutics (SLNO) Stock Forecast & Price Target

SLNO Analyst Ratings

SLNO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Soleno Therapeutics

SLNO Analyst Recommendation Trends

SLNO Financial Forecast

SLNO Earnings Forecast

SLNO Sales Forecast

SLNO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts